


Edited by  
John Whittall | Peter W. Sutton

# Applied Biocatalysis

The Chemist's Enzyme Toolbox



WILEY

# Table of Contents

[Cover](#)

[Abbreviations](#)

[1 Directed Evolution of Enzymes Driving Innovation in API Manufacturing at GSK](#)

[1.1 Introduction](#)

[1.2 Drug Development Stages](#)

[1.3 Enzyme Panels](#)

[1.4 Enzyme Engineering](#)

[1.5 Case Studies](#)

[1.6 Outlook](#)

[Acknowledgements](#)

[References](#)

[2 Survey of Current Commercial Enzyme and Bioprocess Service Providers](#)

[Commercial Enzyme Suppliers/Distributors](#)

[Bioprocess Service Providers](#)

[Chemical Transformations of Selected Commercially Available Enzymes](#)

[Acknowledgements](#)

[Reference](#)

[3 Imine Reductases](#)

[3.1 Imine Reductase-Catalysed Enantioselective Reductive Amination for the Preparation of a Key Intermediate to Lysine-Specific Histone Demethylase 1 \(LSD1\) Inhibitor GSK2879552](#)

[References](#)

[3.2 Expanding the Collection of Imine Reductases Towards a Stereoselective Reductive Amination](#)

[References](#)

[3.3 Asymmetric Synthesis of the Key Intermediate of Dextromethorphan Catalysed by an Imine Reductase](#)

[References](#)

[3.4 Identification of Imine Reductases for Asymmetric Synthesis of 1-Aryltetrahydroisoquinolines](#)

[Acknowledgements](#)

[References](#)

[3.5 Preparation of Imine Reductases at 15 L Scale and Their Application in Asymmetric Piperazine Synthesis](#)

[References](#)

[3.6 Screening of Imine Reductases and Scale-Up of an Oxidative Deamination of an Amine for Ketone Synthesis](#)

[4 Transaminases](#)

[4.1 A Practical Dynamic Kinetic Transamination for the Asymmetric Synthesis of the CGRP Receptor Antagonist Ubrogapant](#)

[References](#)

[4.2 Asymmetric Biosynthesis of L-Phosphinothricin by Transaminase](#)

[References](#)

[4.3 Application of In Situ Product Crystallisation in the Amine Transaminase from \*Silicibacter pomeroyi\*-Catalysed Synthesis of \(S\)-1-\(3-Methoxyphenyl\)ethylamine](#)

## References

### 4.4 Enantioselective Synthesis of Industrially Relevant Amines Using an Immobilised $\omega$ -Transaminase

## References

### 4.5 Amination of Sugars Using Transaminases

## References

### 4.6 Converting Aldoses into Valuable $\omega$ -Amino Alcohols Using Amine Transaminases

## References

## 5 Other Carbon-Nitrogen Bond-Forming Biotransformations

### 5.1 Biocatalytic N-Acylation of Anilines in Aqueous Media

## References

### 5.2 Enantioselective Enzymatic Hydroaminations for the Production of Functionalised Aspartic Acids

## References

### 5.3 Biocatalytic Asymmetric Aza-Michael Addition Reactions and Synthesis of L-Argininosuccinate by Argininosuccinate Lyase ARG4-Catalysed Aza-Michael Addition of L-Arginine to Fumarate

## References

### 5.4 Convenient Approach to the Biosynthesis of C2,C6-Disubstituted Purine Nucleosides Using E. coli Purine Nucleoside Phosphorylase and Arsenolysis

## References

### 5.5 Production of L- and D-Phenylalanine Analogues Using Tailored Phenylalanine Ammonia-Lyases

## References

[5.6 Asymmetric Reductive Amination of Ketones Catalysed by Amine Dehydrogenases](#)

[References](#)

[5.7 Utilisation of Adenylating Enzymes for the Formation of N-Acyl Amides](#)

[References](#)

[6 Carbon-Carbon Bond Formation or Cleavage](#)

[6.1 An Improved Enzymatic Method for the Synthesis of \(R\)-Phenylacetyl Carbinol](#)

[References](#)

[6.2 Tertiary Alcohol Formation Catalysed by a Rhamnulose-1-Phosphate Aldolase : Dendroketose-1-Phosphate Synthesis](#)

[References](#)

[6.3 Easy and Robust Synthesis of Substituted L-Tryptophans with Tryptophan Synthase from Salmonella enterica](#)

[References](#)

[6.4 Biocatalytic Friedel-Crafts-Type C-Acylation](#)

[References](#)

[6.5 MenD-Catalysed Synthesis of 6-Cyano-4-Oxohexanoic Acid](#)

[References](#)

[6.6 Production of \(R\)-2-\(3,5-Dimethoxyphenyl\)propanoic Acid Using an Aryl Malonate Decarboxylase from Bordetella bronchiseptica](#)

[References](#)

[7 Reductive Methods](#)

[7.1 Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High-pH](#)

## [Dynamic Kinetic Reduction](#)

### [References](#)

#### [7.2 Synthesis of a GPR40 Partial Agonist Through a Kinetically Controlled Dynamic Enzymatic Ketone Reduction](#)

### [Reference](#)

#### [7.3 Lab-Scale Synthesis of Eslicarbazepine](#)

### [References](#)

#### [7.4 Direct Access to Aldehydes Using Commercially Available Carboxylic Acid Reductases](#)

### [Acknowledgements](#)

### [References](#)

#### [7.5 Preparation of Methyl \(S\)-3-Oxocyclohexanecarboxylate Using an Enoate Reductase](#)

### [References](#)

## [8 Oxidative Methods](#)

#### [8.1 Macrocyclic Baeyer–Villiger Monooxygenase Oxidation of Cyclopentadecanone on 1 L Scale](#)

### [References](#)

#### [8.2 Regioselective Lactol Oxidation with O<sub>2</sub> as Oxidant on 1 L Scale Using Alcohol Dehydrogenase and NAD\(P\)H Oxidase](#)

### [References](#)

#### [8.3 Synthesis of \(3R\)-4-\[2-Chloro-6-\[\[\[\(R\)-Methylsulfinyl\]methyl\]-Pyrimidin-4-yl\]-3-Methyl-Morpholine Using BVMO-P1-D08](#)

### [Reference](#)

#### [8.4 Oxidation of Vanillyl Alcohol to Vanillin with Molecular Oxygen Catalysed by Eugenol Oxidase on 1 L Scale](#)

## References

8.5 Synthesis of Syringaresinol from 2,6-Dimethoxy-4-Allylphenol Using an Oxidase/Peroxidase Enzyme System

## References

8.6 Biocatalytic Preparation of Vanillin Catalysed by Eugenol Oxidase

## References

8.7 Vanillyl Alcohol Oxidase-Catalysed Production of (R)-1-(4'-Hydroxyphenyl)ethanol

## References

8.8 Enzymatic Synthesis of Pinene-Derived Lactones

## References

8.9 Enzymatic Preparation of Halogenated Hydroxyquinolines

## References

## 9 Hydrolytic and Dehydratase Enzymes

9.1 Synthesis of (S)-3-(4-Chlorophenyl)-4-Cyanobutanoic Acid by a Mutant Nitrilase

## References

9.2 Nitrilase-Mediated Synthesis of a Hydroxyphenylacetic Acid Substrate via a Cyanohydrin Intermediate

## References

9.3 Production of (R)-2-Butyl-2-Ethyloxirane Using an Epoxide Hydrolase from *Agromyces mediolanus*

## References

9.4 Preparation of (S)-1,2-Dodecanediol by Lipase-Catalysed Methanolysis of Racemic Bisbutyrate Followed by Selective Crystallisation

## References

9.5 Biocatalytic Synthesis of n-Octanenitrile Using an Aldoxime Dehydratase from Bacillus sp. OxB-1

## References

9.6 Access to (S)-4-Bromobutan-2-ol through Selective Dehalogenation of rac-1,3-Dibromobutane by Haloalkane Dehalogenase

## Appendix

## References

# 10 Glycosylation, Sulfation and Phosphorylation

10.1 Rutinosidase Synthesis of Glycosyl Esters of Aromatic Acids

## References

10.2 Biocatalytic Synthesis of Kojibiose Using a Mutant Transglycosylase

## References

10.3 Biocatalytic Synthesis of Nigerose Using a Mutant Transglycosylase

## References

10.4 Easy Sulfation of Phenols by a Bacterial Arylsulfotransferase

## References

10.5 Shikimate Kinase-Catalysed Phosphorylations and Synthesis of Shikimic Acid 3-Phosphate by AroL-Catalysed Phosphorylation of Shikimic Acid

## References

10.6 Kinase-Catalysed Phosphorylations of Ketohexose Phosphates and LacC-Catalysed Synthesis of D-Tagatose-1,6-Diphosphate Lithium Salt

## References

[10.7 Kinase-Catalysed Phosphorylations of Xylulose Substrates and Synthesis of Xylulose-5-Phosphate Enantiomers](#)

[References](#)

[10.8 Phosphoramidates by Kinase-Catalysed Phosphorylation and Arginine Kinase-Catalysed Synthesis of N \$\omega\$ -Phospho-L-Arginine](#)

[References](#)

[11 Enzymatic Cascades](#)

[11.1 Redox-Neutral Ketoreductase and Imine Reductase Enzymatic Cascade for the Preparation of a Key Intermediate of the Lysine-Specific Histone Demethylase 1 \(LSD1\) Inhibitor GSK2879552](#)

[References](#)

[11.2 Asymmetric Synthesis of  \$\alpha\$ -Amino Acids through Formal Enantioselective Biocatalytic Amination of Carboxylic Acids](#)

[References](#)

[11.3 Enantioselective, Catalytic One-Pot Synthesis of  \$\gamma\$ -Butyrolactone-Based Fragrances](#)

[References](#)

[11.4 Synthesis of Six out of Eight Carvo-Lactone Stereoisomers via a Novel Concurrent Redox Cascade Starting from \(R\)-and \(S\)-Carvones](#)

[References](#)

[11.5 One-Pot Biocatalytic Synthesis of D-Tryptophan Derivatives from Substituted Indoles and L-Serine](#)

[References](#)

[11.6 Escherichia coli Lysate Multienzyme Biocatalyst for the Synthesis of Uridine-5'-Triphosphate from Orotic Acid and Ribose](#)

## References

11.7 Aerobic Synthesis of Aromatic Nitriles from Alcohols and Ammonia Using Galactose Oxidase

## References

11.8 Hydrogen-Borrowing Conversion of Alcohols into Optically Active Primary Amines by Combination of Alcohol Dehydrogenases and Amine Dehydrogenases

## References

11.9 Ene-Reductase-Mediated Reduction of C=C Double Bonds in the Presence of Conjugated C≡C Triple Bonds: Synthesis of (S)-2-Methyl-5-Phenylpent-4-yn-1-ol

## References

## 12 Chemo-Enzymatic Cascades

12.1 Synergistic Nitroreductase/Vanadium Catalysis for Chemoselective Nitroreductions

## References

12.2 Chemo-Enzymatic Synthesis of (S)-1,2,3,4-Tetrahydroisoquinoline Carboxylic Acids Using D-Amino Acid Oxidase

## References

12.3 Amine Oxidase-Catalysed Deracemisation of (R,S)-4-Cl-Benzhydramine into the (R)-Enantiomer in the Presence of a Chemical Reductant

## References

12.4 Asymmetric Synthesis of 1-Phenylpropan-2-amine from Allylbenzene through a Sequential Strategy Involving a Wacker-Tsuji Oxidation and a Stereoselective Biotransamination

## References

[12.5 Chemoenzymatic Synthesis of \(2S,3S\)-2-Methylpyrrolidin-3-ol](#)

[References](#)

## [13 Whole-Cell Procedures](#)

[13.1 Semipreparative Biocatalytic Synthesis of \(S\)-1-Amino-1-\(3'-Pyridyl\)methylphosphonic Acid](#)

[References](#)

[13.2 Practical and User-Friendly Procedure for the Regio- and Stereoselective Hydration of Oleic, Linoleic and Linolenic Acids, Using Probiotic Lactobacillus Strains as Whole-Cell Biocatalysts](#)

[References](#)

[13.3 Clean Enzymatic Oxidation of 12 \$\alpha\$ -Hydroxysteroids to 12-Oxo-Derivatives Catalysed by Hydroxysteroid Dehydrogenase](#)

[References](#)

[13.4 Whole-Cell Biocatalysis Using PmlABCDEF Monooxygenase and Its Mutants: A Versatile Toolkit for Selective Synthesis of Aromatic N-Oxides](#)

[References](#)

[Index](#)

[End User License Agreement](#)

## **List of Tables**

### Chapter 2

[Table 2.1 Commercial enzyme suppliers/distributors.](#)

[Table 2.2 Bioprocess service providers.](#)

[Table 2.3 Chemical transformations of selected commercially available enzymes](#)

## Chapter 3

[Table 3.1 Primers used for amplification.](#)

[Table 3.2 HPLC method.](#)

[Table 3.3 Retention times for HPLC analysis.](#)

[Table 3.4 Retention times of DHIQs and THIQs in HPLC analysis.](#)

[Table 3.5 HPLC conditions used for the chiral analysis of THIQ products.](#)

[Table 3.6 Conversion and enantioselectivity of selected imine reductases towa...](#)

[Table 3.7 HPLC conditions for analysis of conversion of amine substrate to ke...](#)

## Chapter 4

[Table 4.1 GC method.](#)

[Table 4.2 Retention times for GC analysis.](#)

[Table 4.3 Further substrates.](#)

[Table 4.4 Conversion of monosaccharides \(100 or 200 mM\) \[4\] to the correspond...](#)

## Chapter 5

[Table 5.1 Enantioselective synthesis of \*N\*-heterocycloalkyl-substituted L-aspar...](#)

[Table 5.2 Retention times for HPLC analysis.](#)

[Table 5.3 HPLC methods for the monitoring of enzymatic reactions \(determinati...](#)

[Table 5.4 HPLC methods for the determination of the enantiomeric excess \(ee\) ...](#)

[Table 5.5 Reaction time, conversion, isolation yield and enantiomeric excess ...](#)

[Table 5.6 Substrates accepted by at least one of the reported AmDHs.](#)

[Table 5.7 Enzyme sources.](#)

[Table 5.8 Extinction coefficient \( \$\epsilon\$ \) at  \$\lambda\$  of 280 nm and molecular weight of t...](#)

[Table 5.9 Panel of fatty acid and amine substrates used to screen the TamA-ca...](#)

## Chapter 6

[Table 6.1 Activated ketones used as RhuA electrophiles.](#)

[Table 6.2 Typical conversion to substituted tryptophans catalysed by tryptoph...](#)

[Table 6.3 Reaction buffer.](#)

[Table 6.4 Conditions for reversed-phase chromatography.](#)

[Table 6.5 Chiral SFC method.](#)

## Chapter 8

[Table 8.1 Gradient programme.](#)

[Table 8.2 GC method.](#)

[Table 8.3 Retention times for GC analysis.](#)

[Table 8.4 GC method.](#)

[Table 8.5 Retention times for GC analysis.](#)

[Table 8.6 Reaction components for PCR amplification of rdc2.](#)

[Table 8.7 PCR conditions for amplification of rdc2.](#)

## Chapter 9

[Table 9.1 HPLC method.](#)

[Table 9.2 Retention times for HPLC analysis.](#)

[Table 9.3 TLC method.](#)

[Table 9.4 Retention factors for TLC analysis.](#)

[Table 9.5 HPLC conditions for assessing Nitrilase screening reactions.](#)

[Table 9.6 GC method.](#)

[Table 9.7 Retention times for GC analysis.](#)

[Table 9.8 Aliphatic nitrile synthesis using OxdB in 10 mL scale for different...](#)

## Chapter 10

[Table 10.1 Eluent profile for HPAEC-PAD analysis.](#)

[Table 10.2 Retention times for HPAEC-PAD analysis.](#)

[Table 10.3 Retention times for HPAEC-PAD analysis.](#)

[Table 10.4 Retention times for the sugar-purification system.](#)

## Chapter 11

[Table 11.1 GC-MS programmes used for analysis of  \$\alpha\$ -hydroxy acids.](#)

[Table 11.2 Retention times of substrates and products during GC-MS analysis.](#)

[Table 11.3 Chiral UV-HPLC setup used for analysis of AAs.](#)

[Table 11.4 Retention times of substrates and products for HPLC analysis.](#)

[Table 11.5 Preparative synthesis of L-amino acids \(\*\*1c-5c\*\*\).](#)

[Table 11.6 Enzyme expression strains and expression systems.](#)

[Table 11.7 GC method.](#)

[Table 11.8 One-pot redox reaction of \(+\)-carvone\*\*1a\*\* into the corresponding car...](#)

[Table 11.9 One-pot redox reaction of \(-\)-carvone\*\*1b\*\* into the corresponding car...](#)

[Table 11.10 Data and results from obtained product \(-\)-\(4S,7R\)-7-methyl-4-\(pr...](#)

[Table 11.11 Data and results from obtained product \(-\)-\(3R,6S\)-3-methyl-6-\(p...](#)

[Table 11.12 Data and results from obtained product \(-\)-\(4S,7S\)-7-methyl-4-\(pr...](#)

[Table 11.13 Data and results from obtained product \(-\)-\(4R,7R\)-7-methyl-4-\(pr...](#)

[Table 11.14 Synthesis of D-tryptophan derivatives D-\*\*2b-1\*\* from substitut...](#)

[Table 11.15 Other substrates that can be synthesised via this procedure.](#)

[Table 11.16 HPLC gradient method.](#)

[Table 11.17 Retention times for HPLC analysis.](#)

[Table 11.18 GC method.](#)

[Table 11.19 Retention times for GC analysis.](#)

[Table 11.20 GC retention times and analysis methods for substrates, intermedi...](#)

[Table 11.21 GC retention times and analysis methods for derivatised amine ena...](#)

[Table 11.22 Biocatalytic synthesis of  \$\alpha\$ -chiral amines from alcohols using the...](#)

[Table 11.23 Enzyme sources.](#)

## Chapter 12

[Table 12.1 Additive screening for reduction of NR-14.](#)

[Table 12.2 Substrate scope of NR-04, NR-14, NR-17 and NR-24.](#)

[Table 12.3 Chemo-enzymatic deracemisation of \*rac\*-2a-4a employing FsDAAO....](#)

[Table 12.4 Retention times for LC analysis.](#)

[Table 12.5 GC method for the measurement of product ratios.](#)

[Table 12.6 Retention times for GC analysis using an Agilent HP-1 or HP-5 colu...](#)

[Table 12.7 GC method for the measurement of reaction conversion.](#)

[Table 12.8 Retention times for GC analysis using the Agilent HP-1 column.](#)

[Table 12.9 HPLC method for the measurement of amine enantiomeric excess.](#)

[Table 12.10 Retention times for HPLC analysis using Chiralcel OD column.](#)

[Table 12.11 Sequential cascade process to transform allylbenzenes into optica...](#)

## Chapter 13

[Table 13.1 GC method.](#)

[Table 13.2 Retention times for GC analysis.](#)

[Table 13.3 <sup>1</sup>H-NMR analysis of the \(\*S\*\)-O-acetylmandelate esters derivi...](#)

[Table 13.4 Purification table for E12 \$\alpha\$ -HSDH.](#)

[Table 13.5 Bioconversion tables for Procedures 3 and 4. In both cases, a reac...](#)

## List of Illustrations

### Chapter 1

[Figure 1.1 A general drug discovery path overlapped with biocatalytic opport...](#)

[Scheme 1.1 Selected enzyme classes currently in GSK's collection.](#)

[Figure 1.2 Strategies for generating an enzyme panel.](#)

[Scheme 1.2 Reductive amination of ketones performed by imine reductases.](#)

[Scheme 1.3 Successful synthesis of alkylation products via enzymatic reducti...](#)

[Figure 1.3 Enzyme evolution and biocatalysis adoption.](#)

[Figure 1.4 Design-build-test cycle for an evolution round.](#)

[Scheme 1.4 Epoxide hydrolase \(EH5\)-catalysed resolution of \*rac\*-2-butyl-2-eth...](#)

[Scheme 1.5 Synthesis of chiral synthons for the preparation of SeH inhibitor...](#)

[Scheme 1.6 Nelarabine formation catalysed by PNPase.](#)

[Scheme 1.7 Key chiral amine intermediate for the synthesis of GSK2879552.](#)

[Scheme 1.8 Modified conditions reflecting phosphate buffer synthesis of tert...](#)

## Chapter 3

[Scheme 3.1 Imine reductase M3-catalysed enantioselective reductive amination...](#)

[Scheme 3.2 Reductive amination target and a summary of the genome mining app...](#)

[Figure 3.1 Chiral analysis of the reductive amination catalysed by IR88-2.](#)

[Scheme 3.3 Synthesis of dextromethorphan \*\*1\*\* from 1-\(4-methoxybenzyl\)-3,4,5,6,...](#)

[Scheme 3.4 Asymmetric reduction of DHIQs by imine reductases.](#)

[Scheme 3.5 1-Aryl DHIQ substrates.](#)

[Scheme 3.6 Imine reductase-catalysed preparation of enantiopure \(\*R\*\)-\*N\*-methyl...](#)

[Scheme 3.7 Imine reductase-mediated oxidative deamination.](#)

## Chapter 4

[Scheme 4.1 Industrial-scale production of tert-butyl\(\(5\*S\*,6\*R\*\)-6-methyl-2-oxo-...](#)

[Scheme 4.2 Enzymatic asymmetric synthesis of L-PPT \*\*2\*\* from PPO \*\*1\*\* by Pf-TA.](#)

[Scheme 4.3 Synthesis of IPA-3DPPA salt \(donor salt\) \*\*5\*\*.](#)

[Scheme 4.4 ISPC-based conversion of 3-methoxyacetophenone \*\*1\*\* into \(\*S\*\)-1-\(3-me...](#)

[Scheme 4.5 Synthesis of optically pure \(\*R\*\)-3-amino-1-Boc-piperidine \*\*2\*\*.](#)

[Scheme 4.6 Synthesis of \(R\)-1-\(1-naphthyl\)ethylamine \*\*4\*\*.](#)

[Scheme 4.7 Synthesis of 1-amino-1-deoxy-D-xylitol hydrochloride \*\*1\*\*.](#)

[Scheme 4.8 Synthesis of 2-amino-2-deoxy-D-mannitol hydrochloride \*\*2\*\*.](#)

[Scheme 4.9 \(a\) Overall transformation and conversion of D-deoxyribose to \(2R](#)

## Chapter 5

[Scheme 5.1 Conversion of aniline derivatives to the corresponding acetanilid...](#)

[Scheme 5.2 \(a\) Natural reaction catalysed by EDDS lyase. \(b\) EDDS lyase-cata...](#)

[Scheme 5.3 Selected enzymatic carbon-nitrogen bond-forming Michael addition ...](#)

[Scheme 5.4 Argininosuccinate lyase ARG4-catalysed aza-Michael addition of L-...](#)

[Scheme 5.5 Synthesis of 3'-deoxyriboside 6-methoxyguanine \(6-O-Me-Gua-3'-dR\)...](#)

[Figure 5.4 <sup>1</sup>H-NMR spectrum.](#)

[Scheme 5.6 Ammonia elimination reaction of p-CH<sub>3</sub>-phenylalanine rac-\*\*1a\*\* and am...](#)

[Scheme 5.7 Biocatalytic amination using AmDHs with co-factor recycling.](#)

[Figure 5.2 Comparison of the chemical and biocatalytic routes to the synthes...](#)

[Scheme 5.8 Preparative-scale synthesis of the N-C<sub>12</sub>-L-histidine amide using ...](#)

## Chapter 6

[Scheme 6.1 Enzymatic reactions catalysed by PDC and AHAS enzymes \(Reproduced...](#)

[Scheme 6.2 Enzymatic preparation of R-PAC using CSU-GST of E. coli AHAS I as...](#)

[Scheme 6.3 Preparation of dendroketose-1-phosphate \*\*3\*\* catalysed by rhamnulose...](#)

[Figure 6.2 NMR spectrum for dendroketose-1-phosphate \*\*3\*\*.](#)

[Scheme 6.4 Preparation of substituted L-tryptophans.](#)

[Scheme 6.5 Conversion of resorcinol derivatives \*\*1a-h\*\* to the corresponding ac...](#)

[Scheme 6.6 MenD-catalysed synthesis of 6-cyano-4-oxohexanoic acid \*\*3\*\*.](#)

[Scheme 6.7 Asymmetric synthesis of \(\*R\*\)-2-\(3,5-dimethoxyphenyl\)propanoic acid...](#)

## Chapter 7

[Scheme 7.1 Ketoreductase \(KRED\) designed for activity at high pH and elevate...](#)

[Scheme 7.2 Scalable synthesis of a GPR40 partial agonist enabled by a dynami...](#)

[Scheme 7.3 Series of carbazepine APIs.](#)

[Scheme 7.4 Ketoreductase \(KRED\)-mediated synthesis of \*\*3\*\*.](#)

[Scheme 7.5 Reduction of carboxylic acid \*\*1\*\* to aldehyde \*\*2\*\* with cell-free recyc...](#)

[Scheme 7.6 Selected carboxylic acids.](#)

[Figure 7.1 Screening results of carboxylic acid synthons as substrates for a...](#)

[Scheme 7.7 Preparative-scale reduction of racemic \*\*1c\*\* to aldehyde \*\*2c\*\* using cr...](#)

[Scheme 7.8 ERED-207-mediated reduction of methyl 3-oxocyclohex-1-ene-1-carbo...](#)

## Chapter 8

[Scheme 8.1 Baeyer-Villiger monooxygenase \(BVMO\)-catalysed oxidation of cyclo...](#)

[Figure 8.1 1 L-scale reactor setup used for the Baeyer-Villiger oxidation of...](#)

[Figure 8.2 Progress curve of cyclopentadecaone \(CPD\) oxidation to pentadecal...](#)

[Scheme 8.2 General synthesis route to  \$\delta\$ -lactones \*\*8\*\* via: 2-deoxyribose-5-phos...](#)

[Scheme 8.3 Oxygen and NADP<sup>±</sup> oxidation of lactol \*\*9\*\* derived from DERA reac...](#)

[Figure 8.3 1 L-scale reactor setup used for the oxidation of lactol \*\*9\*\* to hyd...](#)

[Figure 8.4 Progress curve of lactol \*\*9\*\* oxidation with ADH-99 and NOX-01 on 50...](#)

[Scheme 8.4 Synthesis of the chiral sulfoxide \*\*2\*\* using Codexis BVMO P1-D08.](#)

[Scheme 8.5 Reactions catalysed by eugenol oxidase \(EUGO\): target reaction of...](#)

[Scheme 8.6 Oxidation of vanillyl alcohol to vanillin by molecular oxygen cat...](#)

[Figure 8.5 Left: 30 mL- and Right: 1 L-scale reactor set-up used for the oxi...](#)

[Figure 8.6 Example chromatogram of a reference solution.](#)

[Figure 8.7 Progress curve of vanillyl alcohol oxidation by eugenol oxidase \(...\)](#)

[Scheme 8.7 Conversion of 2,6-dimethoxy-4-allylphenol \*\*1\*\* to syringaresinol \*\*3\*\* u...](#)

[Scheme 8.8 Oxidation of vanillyl alcohol \(4-\(hydroxymethyl\)-2-methoxyphenol\)...](#)

[Scheme 8.9 VAO-catalysed conversion of 4-ethylphenol to \(\*R\*\)-1-\(4'-hydroxyphe...](#)

[Scheme 8.10 Conversion of \(–\)-cis-verbenone \*\*2\*\* to the normal pinene-derived l...](#)

[Scheme 8.11 \*In vitro\* and \*in vivo\* enzymatic chlorination of hydroxyquinolines...](#)

## Chapter 9

[Scheme 9.1 Conversion of 3-\(4-chlorophenyl\)glutaronitrile \*\*1\*\* into optically ...](#)

[Scheme 9.2 Nitrilase-mediated synthesis of hydroxyphenylacetic acid derivati...](#)

[Scheme 9.3 Epoxide hydrolase \(EH\) from \*Agromyces mediolanus\* catalysed enanti...](#)

[Scheme 9.4 Procedure for the separation of enantiopure \(\*S\*\)-1,2-dodecanediol ...](#)

[Scheme 9.5 Tosylation of product \(\*S\*\)-\*\*1\*\* for HPLC analysis \[6\].](#)

[Scheme 9.6 Conversion of \*n\*-octanaloxime \*\*1\*\* to \*n\*-octanenitrile \*\*2\*\* using the ald...](#)

[Scheme 9.7 Biocatalytic sequential dehalogenation of \*rac\*-1,3-dibromobutane w...](#)

[Figure 9.1 GC-FID chromatogram trace obtained on a chiral column with separa...](#)

## Chapter 10

[Scheme 10.1 Glycosylation of p-coumaric acid with rutinoidase \[5\].](#)

[Scheme 10.2 Transglucosylation of glucose by double-mutant sucrose phosphory...](#)

[Scheme 10.3 Conversion of sucrose and glucose into kojibiose.](#)

[Figure 10.1 HPAEC-PAD profile of purified kojibiose \(note that the small pea...](#)

[Figures 10.2 \(a\)  \$^1\text{H}\$  NMR and \(b\)  \$^{13}\text{C}\$  NMR spectrum of purified kojibiose.](#)

[Scheme 10.4 Transglucosylation of glucose catalysed by BaSP-YGQF. The disacc...](#)

[Scheme 10.5 Enzymatic Sulfation of \*E\*-resveratrol by arylsulfotransferase \(AS...](#)

[Scheme 10.6 Shikimate kinase-catalysed phosphorylations of cyclic trihydroxy...](#)

[Scheme 10.7 Recombinant \*E. coli\* K12 shikimate kinase AroL-catalysed phosphor...](#)

[Scheme 10.8 Selective kinase-catalysed phosphorylations of D-fructose phosph...](#)

[Scheme 10.9 Enzymatic phosphorylation of D-tagatose-6-phosphate in the 1-pos...](#)

[Scheme 10.10 Selection of xylulokinase-catalysed phosphorylation reactions....](#)

[Scheme 10.11 Comparison of the chemical route \(bottom\) to D-xylulose-5-phosp...](#)

[Scheme 10.12 Selected N-phosphorylation reactions to phosphoramidates cataly...](#)

[Scheme 10.13 Arginine kinase-catalysed N<sub>ω</sub>-phosphorylation of L-arginine...](#)

## Chapter 11

[Scheme 11.1 Enzymatic oxidation-reduction cascade for conversion of \*\*1\*\* into \*\*4\*\*](#)

[Scheme 11.2 One-pot cascade for regio- and enantioselective transformation o...](#)

[Scheme 11.3 Chemoenzymatic synthesis of the quercus lactone \*\*1\*\* \[3\].](#)

[Scheme 11.4 \*Chemoenzymatic synthesis of lactone \*\*6\*\* \[3,6\]. Yields and selectiv...\*](#)

[Scheme 11.5 Catalysis of \(+\)- and \(-\)-carvone into six carvo-lactone stereoi...](#)

[Scheme 11.6 One-pot conversion of indoles \*\*1\*\* into D-tryptophans D-\*\*2\*\*.](#)

[Scheme 11.7 \*Synthesis of UTP \*\*8\*\* from orotic acid \*\*4\*\* and ribose \*\*1\*\* with in situ\*](#)

[Figure 11.1 Workflow for cell lysate biocatalyst preparation and application...](#)

[Scheme 11.8 Biocatalytic cascade catalysed by GOx<sub>M3-5</sub> for the synthesi...](#)

[Scheme 11.9 Biotransformation of 1.2 mmol \(151 mg\) 2'-fluorobenzyl alcohol \*\*1\*\*](#)

[Figure 11.2 Chromatogram of preparative-scale synthesis of \*\*2\*\*. solv, solvent;...](#)

[Scheme 11.10 Elucidated list of substrates accepted by GOx<sub>M3-5</sub>. \[6\].](#)

[Scheme 11.11 One-pot hydrogen-borrowing amination of racemic alcohols into o...](#)

[Scheme 11.12 Homologation of phenylpropionaldehyde \*\*1\*\* into phenylpentynol \(S\)...](#)

[Scheme 11.13 Homologation of aldehydes \*\*1\*\* and \*\*4\*\* into alcohol derivatives \(S\)-...](#)

## Chapter 12

[Scheme 12.1 General reaction scheme for the reduction of nitroaromatics \*\*1\*\* to...](#)

[Scheme 12.2 Reduction of 2-methyl-5-nitropyridine.](#)

[Figure 12.1 Result of fed-batch nitroreduction of 2-methyl-5-nitropyridine....](#)

[Scheme 12.3 Chemo-enzymatic derecemisation of racemic carboxyl-substituted T...](#)

[Scheme 12.4 Overview of the amine oxidase-catalysed deracemisation of \*rac\*-\*\*1\*\* ...](#)

[Figure 12.2 Gene sequence of the R283G variant. The mutated residue is under...](#)

[Figure 12.3 Gene sequence of the Y228L/R283G variant. The mutated residues a...](#)

[Figure 12.4 Gene sequence of the I230A/R283G variant. The mutated residues a...](#)

[Scheme 12.5 Transformation of allylbenzenes \*\*1\*\* into optically active 1-arylpr...](#)

[Scheme 12.6 Wacker-Tsuji oxidation of allylbenzene.](#)

[Scheme 12.7 Biotransamination of 1-phenylpropan-2-one using \(...](#)

[Scheme 12.8 Synthesis of 1-phenylpropan-2-amine enantiomers from allylbenzen...](#)

[Scheme 12.9 Two-step chemo-enzymatic synthesis of iminocyclitols. \(a\) Aldola...](#)

[Scheme 12.10 Two-step chemoenzymatic synthesis of \(2S,3S\)-2-methylpyrrolidin...](#)

## Chapter 13

[Scheme 13.1 Preparation of racemic mixture of 1-amino-1-\(3'-pyridyl\)methylph...](#)

[Scheme 13.2 Bioconversion synthesis of 1-amino-1-\(3'-pyridyl\)methylphosphoni...](#)

[Figure 13.1 Mycelia after immobilisation.](#)

[Figure 13.2 System for continuous-flow column experiments.](#)

[Figure 13.3 <sup>31</sup>P NMR spectra of 1-amino-1-\(3'-pyridyl\)methylphosphonic acid w...](#)

[Scheme 13.3 Lactobacillus strain-mediated biotransformation of oleic acid 1a...](#)

[Scheme 13.4 Oxidation of 12 \$\alpha\$ -OH group of hydroxysteroids catalysed by 12 \$\alpha\$ -HS...](#)

[Figure 13.4 \(a\) Elution profile of E12 \$\alpha\$ -HSDH. The black and grey lines corr...](#)

[Figure 13.5 Scheme of the flow reactor employed in the preparative biotransf...](#)

[Figure 13.6 HPLC analyses of biocatalytic oxidation of CA 1a into 12-oxo-CDC...](#)

[Scheme 13.5 Three different routes in the synthesis of aromatic N-oxides uti...](#)

# **Applied Biocatalysis**

## **The Chemist's Enzyme Toolbox**

*Edited by*

***JOHN WHITTALL***

***University of Manchester Manchester  
UK***

**PETER W. SUTTON**

***Glycoscience S.L. Barcelona ES***

**WILEY**

# Copyright

This edition first published 2021

© 2021 John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of John Whittall and Peter W. Sutton to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

## *Registered Offices*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

## *Editorial Office*

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

## *Limit of Liability/Disclaimer of Warranty*

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organisation, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and

authors endorse the information or services the organisation, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

*Library of Congress Cataloging-in-Publication Data*

Names: Whittall, John, editor. | Sutton, Peter (Peter W.), editor.

Title: Applied biocatalysis : the chemist's enzyme toolbox / edited by Dr John Whittall, Dr Peter W. Sutton.

Description: First edition. | Hoboken, NJ : Wiley, 2021. | Includes bibliographical references and index.

Identifiers: LCCN 2020015374 (print) | LCCN 2020015375 (ebook) | ISBN 9781119487012 (cloth) | ISBN 9781119487029 (adobe pdf) | ISBN 9781119487036 (epub)

Subjects: LCSH: Biocatalysis.

Classification: LCC TP248.65.E59 A677 2021 (print) | LCC TP248.65.E59 (ebook) | DDC 660.6/34-dc23

LC record available at <https://lcn.loc.gov/2020015374>

LC ebook record available at <https://lcn.loc.gov/2020015375>

Cover Design: Wiley

Cover Images: (Background) © Angelatriks/Shutterstock,

(Inset diagram) Courtesy of Gheorghe-Doru Roiban

# Abbreviations

**a/a**

Area/area

**AA**

Amino acid

**AADH**

Amino acid dehydrogenase

**ABTS**

2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid

**ABS**

Amide bond synthetase

**ACN**

Acetonitrile (Also MECN)

**AcOEt**

Ethyl acetate (Also EtOAc)

**ADH**

Alcohol dehydrogenase (Also KRED)

**ADP**

Adenosine diphosphate

**AEAA**

(*S*)-*N*-(2-Aminoethyl)aspartic acid

**AHAS**

Acetohydroxyacid synthase

**AHTC**

Anhydrotetracycline

**AMDase**

Aryl malonate decarboxylase

**AmDH**